← All stocks

BeOne Medicines Ltd.

ONC Net selling
CIK 0001651308 #603 in the set updated 17 Sep 2026
Bought (120 mo)
$947.72M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$6.56B
$175.42M on a plan · $530.50M straight out of an exercise
Sold at will
$5.85B
1039 of 1694 sales
Net
−$5.61B
−$4.90B against sales at will

By person

28 insiders · 1,708 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
HHLR ADVISORS, LTD. entity
10% owner
$4.39B (9)
−$4.39B
125,045,741
$43.92B
−15.0%
OYLER JOHN
Chief Executive Officer
$814.13M (776) scheduled
−$814.13M
6,243,246
$2.19B
+131.1%
Wang Xiaodong
Director
$153.69M (271) scheduled
−$153.69M
4,588,163
$1.61B
−57.5%
Wu Xiaobin
President and COO
$104.80M (150) scheduled
−$104.80M
1,308,161
$459.50M
AMGEN INC entity
10% owner
$50.00M (1)
+$50.00M
255,193,647
$89.64B
+13.5%
Liang Howard
CFO & Chief Strategy Officer
$48.84M (58) scheduled
−$48.84M
1,573,715
$552.77M
BAKER BROS. ADVISORS LP entity
Director
$896.76M (8)
$943.56M (16)
−$46.80M
8,283,488
$2.91B
Huang Jane
CMO, Hematology
$39.74M (199) scheduled
−$39.74M
160,055
$56.22M
Lee Chan Henry
SVP, General Counsel
$16.39M (44) scheduled
−$16.39M
346,554
$121.73M
Glazer Donald W.
Director
$12.66M (17)
−$12.66M
2,718,464
$954.87M
−36.1%
Wang Lai
President, Global Head of R&D
$9.98M (46) scheduled
−$9.98M
1,710,085
$600.67M
Peterson Amy C.
CMO, Immuno-oncology
$8.76M (38) scheduled
−$8.76M
269,566
$94.69M
+2.7%
Chen Timothy Yung-Cheng
Director
$6.37M (30) scheduled
−$6.37M
7,800
$2.74M
Sanders Corazon (Corsee) D.
Director
$1.96M (6) scheduled
−$1.96M
57,226
$20.10M
Li Ji
EVP and Gl. Head of Bus. Dev.
$1.47M (6) scheduled
−$1.47M
0
$0.00
Malley Thomas
Director
$960.00K (1)
+$960.00K
76,696
$26.94M
Wang Julia Aijun
Chief Financial Officer
$953.45K (14)
−$953.45K
456,326
$160.29M
+786.4%
Rosenberg Aaron
Chief Financial Officer
$870.11K (3)
−$870.11K
397,891
$139.76M
Ball Titus B.
Principal Accounting Officer
$227.85K (8)
−$227.85K
97,929
$34.40M
+624.4%
Dugan Margaret
Director
$65.64K (1)
−$65.64K
73,164
$25.70M
Riva Alessandro
Director
$65.62K (1)
−$65.62K
73,164
$25.70M
Yi Qingqing
Director
$65.60K (1)
−$65.60K
27,326
$9.60M
+11,938%
HOOPER ANTHONY C
Director
83,720
$29.41M
BRANDICOURT OLIVIER
Director
46,306
$16.27M
Sharp Shalini
Director
38,116
$13.39M
Sawyers Charles Lazelle
Director
18,984
$6.67M
+474,500%
Mooney Elizabeth Fisher
Director
18,980
$6.67M
su Jingshyh S
Director
7,800
$2.74M

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 510
Amendments (4/A) skipped 3
Filings about a different issuer 1
Unreadable filings 0
Joint filings 26
Sales on a Rule 10b5-1 plan 125
Sales straight out of an exercise 530
Sales at will 1,039
Transactions with no price 0
Shares from compensation/vesting 87,064,557
Sales filed before the plan box existed 868
History held since 7 Sep 2016